@article{3220693,
    title = "Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial",
    author = "Zagouri, F. and Koliou, G.-A. and Dimitrakopoulos, F. and Papadimitriou, C. and Binas, I. and Koutras, A. and Papakostas, P. and Markopoulos, C. and Venizelos, V. and Xepapadakis, G. and Andrikopoulou, Α. and Karanikiotis, C. and Psyrri, A. and Bafaloukos, D. and Kosmidis, P. and Aravantinos, G. and Res, E. and Mauri, D. and Koumarianou, A. and Petraki, K. and Tsipoura, A. and Pectasides, D. and Gogas, H. and Fountzilas, G.",
    journal = "British Journal of Cancer",
    year = "2022",
    publisher = "Springer Nature BV",
    issn = "0007-0920, 1532-1827",
    doi = "10.1038/s41416-022-01846-y",
    abstract = "Background: Dose-dense sequential chemotherapy with anthracyclines and taxanes achieved an 18% reduction of recurrence risk in early breast cancer (BC). The optimal chemotherapy schedule and interval between cycles remain under investigation. Methods: Overall, 990 patients were randomised to receive either three cycles of epirubicin (E, 110 mg/m2) every 2 weeks followed by 3 cycles of paclitaxel (T, 200 mg/m2) every 2 weeks followed by three cycles of intensified CMF (Control Arm A, E-T-CMF) that was previously used in BC or three cycles of epirubicin followed by three cycles of CMF followed by nine consecutive weekly cycles of docetaxel (wD) 35 mg/m2 (Arm B, E-CMF-wD) or nine consecutive weekly cycles of paclitaxel (wT) 80 mg/m2 (Arm C, E-CMF-wT). Trastuzumab was administered for HER2-positive disease. Results: At a median follow-up of 13.3 years, 330 disease-free survival (DFS) events (33.3%) were reported. DFS and overall survival (OS) did not differ between patients in the combined B and C arms versus arm A either in the entire cohort (HR = 0.90, P = 0.38 and HR = 0.85, P = 0.20) or among trastuzumab-treated patients (HR = 0.69, P = 0.13 and HR = 0.67, P = 0.13). Thirty-four patients (3.4%) developed secondary neoplasms. Conclusions: Overall, no significant differences in survival were found amongst the studied regimens after a long-term observational period. Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12610000151033. © 2022, The Author(s), under exclusive licence to Springer Nature Limited."
}